POZEN INC. v. Par Pharmaceutical, Inc.
800 F. Supp. 2d 789
E.D. Tex.2011Background
- Pozen sued Par, Alphapharm, and DRL alleging patent infringement under the Hatch-Waxman framework for Treximet (sumatriptan–naproxen) with patents 6,060,499 ('499), 6,586,458 ('458), and 7,332,183 ('183).
- The case proceeded to a five-day bench trial after a Markman ruling, addressing infringement, noninfringement, invalidity, and unenforceability.
- Pozen alleged that Defendants’ ANDAs would infringe the asserted patents directly or through inducement, and that Treximet’s label and packaging met asserted claim limitations.
- The court construed key claim terms, including “therapeutic package,” “finished pharmaceutical container,” and “concomitant/concomitantly,” and evaluated each patent’s applicability to the accused products.
- Defendants stipulated to certain claim limitations in '458 and acknowledged the pharmaceutical/product equivalence of their products for purposes of the trial.
- The court ultimately held that Pozen proved direct infringement of the '499 patent (claim 15) and the asserted '458 claims; that Par and DRL infringe the '183 patent under the doctrine of equivalents; that the asserted patents are not invalidated by the cited references; and that a permanent injunction should issue.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Infringement of the '499 patent (claim 15) | Pozen contends Defendants’ ANDAs meet all elements of claim 15 (unit dose with sumatriptan and naproxen in a finished container with proper labeling). | Defendants argue their products and labeling do not satisfy the claimed packaging/labeling limitations. | Direct infringement proved. |
| Inducement of infringement of the '499 patent | Inducement shown by ANDA filings and accompanying labeling directing infringing use. | Inducement not properly pled/limited; packaging not directing infringement. | Inducement established. |
| Validity of the '458 and '499 patents (anticipation/obviousness) | References cited do not teach the claimed simultaneous administration and long-lasting efficacy. | References (Catarci, Parma, Saadah, Henry Ford records, WO 1998/06392) render claims obvious or anticipated. | Not shown to be obvious/anticipated by clear and convincing evidence. |
| Validity of the '183 patent | Doctrine of equivalents supports infringement despite nonliteral layer construction. | Literal/nonliteral distinctions preclude equivalence; prosecution history disfavors broad reading. | Not invalid; DOEs supported; Tri-layer/bilayer architecture upheld. |
| Inequitable conduct/ unenforceability | Pozen did not intentionally mislead the PTO; data analyses were properly presented. | Omissions/misrepresentations to PTO. | Not unenforceable for inequitable conduct. |
Key Cases Cited
- Microsoft Corp. v. i4i Ltd., 131 S. Ct. 2238 (U.S. 2011) (clear-and-convincing standard; burden of validity on patentee)
- Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) (but-for materiality; intent required for inequitable conduct)
- DSU Med. Corp. v. JMS Co., 471 F.3d 1293 (Fed. Cir. 2006) (inducement requires culpable conduct toward infringement)
- Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003) (indirect infringement requires direct infringement predicate)
- Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950) (essence of equivalence: substantial sameness in function/way/result)